BR112018014668A2 - multímeros de fc de igg recombinante - Google Patents

multímeros de fc de igg recombinante

Info

Publication number
BR112018014668A2
BR112018014668A2 BR112018014668-4A BR112018014668A BR112018014668A2 BR 112018014668 A2 BR112018014668 A2 BR 112018014668A2 BR 112018014668 A BR112018014668 A BR 112018014668A BR 112018014668 A2 BR112018014668 A2 BR 112018014668A2
Authority
BR
Brazil
Prior art keywords
multimers
recombinant igg
igg
recombinant
administering
Prior art date
Application number
BR112018014668-4A
Other languages
English (en)
Inventor
SPIRIG Rolf
KAESERMANN Fabian
Zuercher Adrian
Panousis Con
BAZ MORELLI Adriana
Chen Chao-Guang
Original Assignee
Csl Behring Recombinant Facility Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Recombinant Facility Ag filed Critical Csl Behring Recombinant Facility Ag
Publication of BR112018014668A2 publication Critical patent/BR112018014668A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

esta descrição refere-se a multímeros de fc de igg recombinante e métodos para o tratamento de doenças autoimunes e inflamatórias pela administração de tais multímeros.
BR112018014668-4A 2016-01-27 2017-01-27 multímeros de fc de igg recombinante BR112018014668A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16152867.4 2016-01-27
EP16152867 2016-01-27
EP16162166.9 2016-03-24
EP16162166 2016-03-24
EP16195116 2016-10-21
EP16195116.5 2016-10-21
PCT/EP2017/051757 WO2017129737A1 (en) 2016-01-27 2017-01-27 Recombinant igg fc multimers

Publications (1)

Publication Number Publication Date
BR112018014668A2 true BR112018014668A2 (pt) 2018-12-11

Family

ID=57956274

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018014668-4A BR112018014668A2 (pt) 2016-01-27 2017-01-27 multímeros de fc de igg recombinante

Country Status (13)

Country Link
US (1) US20190119377A1 (pt)
EP (1) EP3408279A1 (pt)
JP (1) JP2019511458A (pt)
KR (1) KR20180100701A (pt)
CN (1) CN108602857A (pt)
AU (1) AU2017213117A1 (pt)
BR (1) BR112018014668A2 (pt)
CA (1) CA3012037A1 (pt)
HK (1) HK1258166A1 (pt)
MX (1) MX2018008339A (pt)
RU (1) RU2018130525A (pt)
SG (2) SG10201911561SA (pt)
WO (1) WO2017129737A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116970061A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118A4 (en) 2017-03-15 2021-04-07 Cue Biopharma, Inc. PROCESSES FOR MODULATING AN IMMUNE RESPONSE
EP3723791B1 (en) * 2017-12-14 2024-02-21 CSL Behring Lengnau AG Recombinant igg fc multimers for the treatment of neuromyelitis optica
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
SG11202011969WA (en) 2018-08-30 2020-12-30 Regeneron Pharma Methods for characterizing protein complexes
WO2020121282A1 (en) 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use
KR20220062084A (ko) 2019-09-13 2022-05-13 체에스엘 베링 렝나우 아게 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체
CA3146591A1 (en) * 2019-09-20 2021-03-25 Ronald D. Seidel Iii T-cell modulatory polypeptides and methods of use thereof
US20240092889A1 (en) * 2019-10-16 2024-03-21 Chugai Seiyaku Kabushiki Kaisha An antibody, a pharmaceutical composition, and a method
AU2020394844A1 (en) 2019-12-06 2022-06-30 CSL Behring Lengnau AG Stable compositions of Fc multimers
CA3169949A1 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN114894911B (zh) * 2022-03-18 2023-10-24 辽宁成大生物股份有限公司 一种控制牛血清产品质量方法
CN118027155A (zh) * 2024-04-15 2024-05-14 中国人民解放军军事科学院军事医学研究院 一种tpor结合肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2849765C (en) * 2011-09-26 2021-10-19 Jn Biosciences Llc Hybrid constant regions
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US20150218236A1 (en) * 2012-10-17 2015-08-06 Liverpool School Of Tropical Medicine Immunomodulatory proteins
EP3114137A1 (en) * 2014-03-05 2017-01-11 UCB Biopharma SPRL Multimeric fc proteins
JP6851200B2 (ja) * 2014-03-05 2021-03-31 ユーシービー バイオファルマ エスアールエル 多量体Ｆｃタンパク質

Also Published As

Publication number Publication date
RU2018130525A (ru) 2020-02-27
KR20180100701A (ko) 2018-09-11
WO2017129737A1 (en) 2017-08-03
MX2018008339A (es) 2018-09-17
HK1258166A1 (zh) 2019-11-08
AU2017213117A1 (en) 2018-07-19
RU2018130525A3 (pt) 2020-05-29
JP2019511458A (ja) 2019-04-25
US20190119377A1 (en) 2019-04-25
EP3408279A1 (en) 2018-12-05
CN108602857A (zh) 2018-09-28
CA3012037A1 (en) 2017-08-03
SG11201805579SA (en) 2018-08-30
SG10201911561SA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
BR112018014668A2 (pt) multímeros de fc de igg recombinante
CL2018003322A1 (es) Inhibidores peptídicos del receptor de interleucina 23 y sus uso para tratar enfermedades inflamatorias. (divisional solicitud 201800128)
CL2016001968A1 (es) Proteinas de fusion de interleucina-2 y usos de las mismas
EA202190903A2 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
BR112018009706A2 (pt) composições compreendendo cepas bacterianas
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
BR112017025003A2 (pt) composições compreendendo cepas bacterianas
MD3650033T2 (ro) Compoziții conţinând tulpini bacteriene
EA201691974A1 (ru) Антитела против ox40 и способы их применения
UY36021A (es) Proteìnas fc multimèricas
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
CL2016000392A1 (es) Análogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
CY1123116T1 (el) Θεραπευτικη αντιμετωπιση των αυτοανοσων διαταραχων με cd154 αντισωματα
EA201890340A1 (ru) Моноклональное антитело-ингибитор фактора xiia
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
DK3229827T3 (da) Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CSL BEHRING LENGNAU AG (CH)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2655 DE 23-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.